Aarti Drugs Receives Crisil ESG 61 Strong Rating

Date: October 8, 2026

ESG Rating Disclosure

Aarti Drugs Limited has received an Environmental, Social, and Governance (ESG) Rating of 'Crisil ESG 61 (Strong)' from Crisil ESG Ratings & Analytic Limited, a SEBI registered Category-1 ESG Rating Provider. The rating is based on data pertaining to FY 2025-26.

Rating Provider Information

Crisil ESG Ratings & Analytic Limited prepared the report independently without engagement by the company. The rating was based on FY 2025-26 data available in the public domain. The report was received by the company on October 7, 2026.